Fenofibrate and Diosmetin in a rat model of testicular toxicity: New insight on their protective mechanism through PPAR-α/NRF-2/HO-1 signaling pathway

• Published in: Biomedicine & pharmacotherapy Vol. 165; p. 115095
• Main Authors: Alqahtani, Moneerah J., Negm, Walaa A., Saad, Hebatallah M., Salem, Esraa A., Hussein, Ismail A., Ibrahim, Hanaa A.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-09-2023; Elsevier
• Subjects: Apoptosis; Cisplatin; Diosmetin; Fenofibrate; Inflammation; Oxidative stress; Fenofibrate; Diosmetin; Oxidative stress; Inflammation; Cisplatin; Apoptosis
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115095

One of the most significant chemotherapeutic side effects of cisplatin (Cis) that limits its use and efficacy is testicular toxicity. Thus, the objective of the present study was to investigate the possible ameliorative effect of Fenofibrate (Fen), Diosmetin (D), and their combination against cis-mediated testicular damage. Fifty-four adult male albino rats were randomly allocated into nine groups (6 rats each): Control group, Fen (100 mg/kg), D20 (20 mg/kg), D40 (40 mg/kg), Cis group (7 mg/kg), Cis +Fen group (7 mg/kg+100 mg/kg), Cis+D20 group (7 mg/kg+20 mg/kg), Cis+D40 group (7 mg/kg+40 mg/kg), Cis+Fen+D40 treated group (7 mg/kg+100 mg/kg+40 mg/kg). Relative testicular weight, epididymal sperm count and viability, serum testosterone level, testicular oxidative stress indices, mRNA expression of peroxisome proliferator-activated receptor alpha (PPAR-α), nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1), histopathological, and immunohistochemical alterations were assessed. Our results revealed that cis administration induced testicular oxidative and inflammatory damage as indicated by a substantial reduction in relative testicular weight, sperm parameters, serum testosterone levels, the antioxidant enzyme activity of catalase, and Johnson's histopathological score, PPAR-α/NRF-2/HO-1 and proliferating cell nuclear antigen (PCNA) immunoexpression with marked increment in malondialdehyde (MDA), Cosentino's score, nuclear factor kappa B (NF-κβ p65), interleukin (IL)− 1β and caspase 3 in testicular tissue. Interestingly, Fen and D diminished the harmful effects of cis on testes via upregulation of the antioxidant activities and downregulation of lipid peroxidation, apoptosis, and inflammation. Moreover, the combination therapy Fen/D40 also exhibited a more pronounced enhancement of previous markers than either treatment alone. In conclusion, because of their antioxidant, anti-inflammatory, and anti-apoptotic properties, cotreatment with Fen or D or their combination could be beneficial in reducing the harmful impacts of cis on testicular tissue, particularly in patients that receive cis chemotherapy.
[Display omitted]
•Fenofibrate or diosmetin or their combination could be beneficial in reducing the harmful impacts of cisplatin-induced testicular cytotoxicity via PPAR-α/NRF-2/HO-1.•Cis administration resulted in substantial reduction in relative testicular weight, sperm count and viability, serum testosterone levels, antioxidant enzyme activity of catalase, and Johnson's score, PPAR-α/NRF-2/HO-1 and proliferating cell nuclear antigen (PCNA) immunoexpression.•Cis administration associated with marked increment in malondialdehyde (MDA), Cosentino’s score, nuclear factor kappa B (NF-κβ p65), interleukin (IL)−1β and caspase 3 in testicular tissue.•Fenofibrate and diosmetin have antioxidant, anti-inflammatory, and anti-apoptotic properties.